stocktive logo
United States ▻ Healthcare
Bristol-Myers Squibb
NYSE:BMY
Tea Leaves Summary
Bristol-Myers Squibb [NYSE:BMY] share price
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Quick Section Links
→ Sentiment
sentiment score
→ Positions
positions score
→ Growth
growth score
→ Value
value score
→ Health
health score
→ Earth
earth score
Page Updated: Aug 19, 2019

Bristol-Myers Squibb [NYSE:BMY] share price, stock quote Analysis

What has the stock performance of Bristol-Myers Squibb been like?
stock quote price chart

Bristol-Myers Squibb's (NYSE:BMY) stock is 18.5% lower in the past 12 months and has underperformed the overall US TECH market which is 3.9% higher in the same timeframe. This is equivalent to a -22.3% lower return over the period which puts the stock as an underperformer vs other US TECH companies.

Sentiment

Tea Leaves Score
sentiment tea score

Analyst RatingS

What are analyst ratings for Bristol-Myers Squibb?
Analyst Ratings
Analyst Ratings Change
analyst ratings

From 22 analysts that cover Bristol-Myers Squibb's stock, the average rating is 3.5. This is a weighted average of 5 strong buys, 4 buys, 11 holds, 2 sells. This is 0.2 lower than a month ago which gives this factor a tea-score of 2/5.

Positions

Tea Leaves Score
positions tea score

Insider Trades

What has Bristol-Myers Squibb's insider trading been over the past year?
Sold
Bought
insider trading chart

Bristol-Myers Squibb insider's have net been buying stock over the past 12 months, in the previous month insiders have been net buying. In fact the buy to sell ratio in the past month has been 50.0% which is 50.7% lower than the last 12 months buy to sell ratio. This put's Bristol-Myers Squibb's Insiders in the top quintile vs their peers giving this factor a tea-score of 3/5.

Ownership

What is the ownership of Bristol-Myers Squibb stock?
ownership chart

For Bristol-Myers Squibb, currently 75.0% of stock (1 billion shares) is owned by Institutions, 24.8% (802 million shares) is owned by Individuals, and 0.1% (2 million shares) is owned by company insiders. The CEO has a holding of 0.02% which is equivalent to 40 thousand shares with a market value of $129 million. This factor has a tea-score of 4/5.

Short Interest

What is the short interest for Bristol-Myers Squibb stock?
short interest chart

As of 31 July 2019, the short interest for Bristol-Myers Squibb has been 7.60% of the shares outstanding which is 1 trillion shares. This is more than 1 month ago which had 6.82% of the shares outstanding which is 1 trillion short interest in shares. This equals a tea-score of 2/5.

Growth

Tea Leaves Score
growth tea leaves

Revenue & Earnings

What has Bristol-Myers Squibb's revenue history been by year?
revenue chart

Bristol-Myers Squibb's revenue in the last 12 months ending 30 June 2019 is $23Bn. Bristol-Myers Squibb's average revenue growth for the last 4 years has been 5.1% which is currently lower than their comps of 6.2%.

Free Cash Flow Yield Growth

What is Bristol-Myers Squibb's free cash flow yield?
free cash flow yield chart

Bristol-Myers Squibb's free cash flow yield is 6.0% and has grown from 4 years ago. The free cash flow yield for Bristol-Myers Squibb 1 year ago was 4.4% and 3 years ago it was 1.2%.

Dividend History & yield

What has Bristol-Myers Squibb's dividend payments been historically?
Dividend ($)
Dividend Yield (%)
dividend chart

Bristol-Myers Squibb pays dividends every 3 months and has done so since 02 April 2013. Dividends have been steadily increasing over the past 4 years from $0.37 (dividend yield of 0.60%) to $0.41 today (yield of 0.88%).

Value

Tea Leaves Score
value tea leaves

PE Ratio

What is Bristol-Myers Squibb's PE ratio?
pe ratio

Bristol-Myers Squibb's PE ratio is 12.4x. This is calculated from their EPS of $2.02 and price per share of $46.98. Bristol-Myers Squibb's PE ratio values the company cheaper than 20% of it's competitors giving this factor a tea-score of 1/5.

PEG Ratio

What is Bristol-Myers Squibb's PEG ratio?
peg ratio

Bristol-Myers Squibb's PEG ratio is 0.0x. This is calculated from their PE ratio of 12.4x and their last 12 months growth rate of 2.839%. This is more attractive than their competitors so the tea-score for this factor is 1/5.

Share Price / Book (PB Ratio)

What is Bristol-Myers Squibb's PB ratio?
PB ratio

The PB ratio for Bristol-Myers Squibb is 4.8x. This is more expensive than their competitors who have an average PB ratio of 3.8x. The tea-score is 4/5.

Free Cash Flow Yield

What is Bristol-Myers Squibb's free cash flow yield?
free cash flow yield

Bristol-Myers Squibb's free cash flow yield is 6.0% which is ranked 1.0/5 when compared to its competitors. This is calculated from a free cash flow of - (as reported for the 12 months ending 30 June 2019) divided by its current market capitalisation of $76Bn. The average free cash flow yield across Bristol-Myers Squibb's comps is 8.1%.

Return On Investment (ROI)

What is Bristol-Myers Squibb's return on investment (ROI)?
return on investment

Bristol-Myers Squibb's return on investment is 43.6%. This is more profitable than its competitors.

Health

Tea Leaves Score
health tea leaves

Assets vs Liabilities

What is Bristol-Myers Squibb's current ratio (assets vs liabilities)?
assets vs liabilities

Bristol-Myers Squibb's current ratio is calculated by (current assets) / (current liabilities) which equals 3.9x. This less attractive than their competitors and also worse than recommended for a healthy company.

Debt vs Equity

What is Bristol-Myers Squibb's debt vs shareholder equity?
debt vs equity

Bristol-Myers Squibb's debt to shareholder equity is 159.7%. This is worse than their competitors and also worse than advised for a well-managed balance sheet.

Dividend Payout Ratio

What is Bristol-Myers Squibb's dividend payout ratio?
dividend payout ratio

Bristol-Myers Squibb's dividend payout ratio calculated against their free cash flow is low at 62.2%. This is in quintile 2 when measured against their comps.

Earth

Tea Leaves Score
ESG score
What is the overall ESG (environmental, social and corporate governance) rating for Bristol-Myers Squibb?

Bristol-Myers Squibb's has a good overall ESG rating of 66/100. Their competitors have a score between 38 and 79 with the average at 58.

ESG Environmental

What the latest (ESG) environmental responsibility score for Bristol-Myers Squibb vs their competitors?
ESG environmental
We can see here what the environmental consciousness of Bristol-Myers Squibb is relative to other similar companies.

ESG Social

What the present (ESG) social responsibility score for Bristol-Myers Squibb vs their peers?
ESG social
We can get a sense of what the social responsbility of Bristol-Myers Squibb is when compared to other rival companies.

ESG Corporate Governance

What the current (ESG) corporate governance score for Bristol-Myers Squibb vs their challengers?
ESG corporate governance
With this number we can understand what the corporate governance of Bristol-Myers Squibb is when compared to it's peers.

APPLE [NASDAQ:AAPL] COMPANY PROFILE

Description

What is the company description of Bristol-Myers Squibb?
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases.

Bristol-Myers Squibb [NYSE:BMY] Additional Q&A

Questions & Answers

What is the 52 week high for Bristol-Myers Squibb stock quote?

Bristol-Myers Squibb (NYSE:BMY) hit a new 52-week high on 09 October 2018 at a price of $62.19 with 6,618,700 shares traded that day. This is 32.4% higher than than its current price of $46.98 and 45.4% higher than the 52-week low of $42.77 on 22 July 2019. Average daily volume traded has been 13 million shares over the past 3 months.

What is the highest price Bristol-Myers Squibb stock has ever been?

The all-time highs for Bristol-Myers Squibb stock were reached on 09 October 2018, 314 days ago at a price of $62.19. This equates to a market capitalisation of $101Bn. The highest price reached is 32.4% higher than the current price of $46.98 with a current market cap of $76Bn.

What is the beta of Bristol-Myers Squibb stock?

Bristol-Myers Squibb stock moves 0.7x the US TECH market average which makes its beta higher than the overall market.

What is the volatility of Bristol-Myers Squibb (BMY) stock?

Bristol-Myers Squibb's stock has an annual volatility of 28.9% which is more volatile than the average US TECH market volatility of 16.3% which has made it a less safe stock to own in the past vs just owning the index for investors aiming for lower portfolio volatility.

What have Bristol-Myers Squibb's share buybacks been over the past year?

Bristol-Myers Squibb is currently running a share-buyback program and in the past year alone the company has repurchased 104 million of shares outstanding at a total expense of $23Trn. In the same time frame the share price has moved 18.5% lower which is an underperformance of -22.3% vs the overall market. Bristol-Myers Squibb still has $420Trn of cash remaining on their balance sheet.

Who owns the most Bristol-Myers Squibb stock?

Barry White is the largest individual shareholder in Bristol-Myers Squibb with 1 billion shares. He is an independent director of Bristol-Myers Squibb. The largest institutional holder is T-Rowe and they own 6.1% of the issue size with 100 million shares. T-Rowe have been net buying shares over the last 12 months as they own 1 million more shares than a year ago.

When did Bristol-Myers Squibb beat earnings expectations in the last 4 years?

In the past 4 quarters Bristol-Myers Squibb has had 3 earnings beat's and 1 earnings miss's. The average earnings beat has been 12.1% and the average earnings miss has been 8.2%.

When is Bristol-Myers Squibb's next earnings date and what are the expectations?

Bristol-Myers Squibb is set to report earnings on 30 July 2019 after market close. The report will be for the fiscal Quarter ending June 2019. Based on 14 analysts' forecasts, the consensus EPS forecast for the quarter is $2.12. Recent analyst revisions have been positive implying a potential EPS of $2.24.

What is Bristol-Myers Squibb's upcoming earnings report expectations?

The earnings expectations for Bristol-Myers Squibb's upcoming report on 30 July 2019 are from 14 analysts with an average EPS of $2.12. The lowest analyst rating is $2.01, the highest is $2.84. The most recent earnings revisions have been positive with a most recent estimate of $2.24.

What is Bristol-Myers Squibb's earnings per share (EPS)?

Bristol-Myers Squibb's latest earnings per share (EPS) was reported as $2.02 on 30 April 2019 for fiscal quarter ending March 2019. This is 11.0% higher than 12 months ago when they reported EPS of $1.82

What is Bristol-Myers Squibb's dividend growth rate?

Bristol-Myers Squibb's dividends have grown at 2.50% in the past year and an average growth of 2.70% over the past 4 years. This is lower then it's competitors 4-year average dividend growth of 4.1

What is Bristol-Myers Squibb's dividend yield?

Bristol-Myers Squibb's current dividend yield is 0.88%. This is calculated by taking the dividend's per share of $0.41 (the last payment which was on 03 July 2019) and dividing by the current share price of $46.98.

What is Bristol-Myers Squibb's previous and next dividend date?

Bristol-Myers Squibb's most recent dividend date was 03 July 2019 when the company paid $0.41 and the next dividend date is 01 October 2019 with an expected payment of $0.41.

By using this website, you accept our Terms of Use and Privacy Policy. Stocktive is not a registered investment advisory service and the information presented on this site is not intended for investment purposes. You can find out more about the team that built Stocktive on our team page. If you'd like investment advisory services we have an investment partner. Nothing on this website should be considered an offer, solicitation of an offer, or advice to buy or sell securities. Past performance is no guarantee of future results. Any historical returns, expected returns or probability projections are hypothetical in nature and may not reflect actual future performance. The analysis presented herein, the stock price, and anything related are for illustrative purposes only and are not investment recommendations. If you'd like further information about fundamental analysis you can check out a detailed wiki page.
© 2019 StockForecast
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.